Record Nr. UNINA9910254558403321 Immunotherapy of Cancer: An Innovative Treatment Comes of Age // **Titolo** edited by Yoshiyuki Yamaguchi Pubbl/distr/stampa Tokyo:,: Springer Japan:,: Imprint: Springer,, 2016 **ISBN** 4-431-55031-3 Edizione [1st ed. 2016.] Descrizione fisica 1 online resource (351 p.) Disciplina 616.994079 Soggetti Oncology Cancer research **Immunology** Oncology Cancer Research Lingua di pubblicazione Inglese **Formato** Materiale a stampa Livello bibliografico Monografia Description based upon print version of record. Note generali Nota di bibliografia Includes bibliographical references. Nota di contenuto Part I Overview, History, Classification -- Chapter 1 Overview of Current Cancer Immunotherapy -- Part II BRMs and Crude Agents -- Chapter 2 Bacterial Preparations -- Chapter 3 Polysaccharides -- Chapter 4 BCG -- Part III Cytokines -- Chapter 5 -T Cells -- Chapter 6 NKT Cell-Based Immunotherapy -- Chapter 7 Natural Killer Cells -- Chapter 8 T Cell-Based Cancer Immunotherapy -- Chapter 9 Genetically engineered T cells -- Part IV Vaccine Therapy -- Chapter 10 Peptide Vaccine -- Chapter 11 Personalized Peptide Vaccine -- Chapter 12 WT1 Peptide Vaccine for the Treatment of Malignancies -- Chapter 13 Protein vaccine -- Chapter 14 Dendritic Cell-Based Vaccine for Cancer -- Part V Immunoadjuvants -- Chapter 15 CpG Motif -- Chapter 16 Pattern Recognition by Dendritic Cells and Its Application to Vaccine Adjuvant for Antitumor Immunotherapy -- Chapter 17 Novel Adjuvants -- Part VI Immunocheckpoints -- Chapter 18 Anti-CTLA-4 Ab --

Chapter 19 Anti-PD-1, PD-L1 Ab -- Chapter 20 Novel Targets of

Response Criteria and Guidance for Clinical Trials -- Chapter 23

Immune Inhibitory and Stimulatory Co-signals -- Part VII Regulation of Immunosuppression -- Chapter 21 Regulatory T Cells -- Chapter 22 MDSC: Myeloid-Derived Suppressor Cells -- Part VIII Immune-Related

Sommario/riassunto

Immune-Related Response Criteria and Guidance for Clinical Trials -- Part IX Personalized Immunotherapy -- Chapter 24 ersonalized cancer immunotherapy: Immune biomarkers and combination immunotherapy.

This timely book, published just as cancer immunotherapy comes of age, summarizes the rationale, present status, and future perspective for cancer immunotherapy. Included are explanations of the constitution of the immune system and immunocheckpoints, the mechanism of antigen presentation and recognition, valuable modalities, clinical trials and guidance, personalization, and biomarkers, all of which are essential for understanding the success of cancer immunotherapy. This innovative therapy has been investigated worldwide as the fourth line of cancer treatment after the standard treatments of surgery, chemotherapy, and radiotherapy. The progress in fundamental understanding of tumor immunology and the recent advances in clinical trials have opened new avenues with a cancer vaccine in 2010 and immunocheckpoint modulation in 2011, with their approval already granted in the United States. Today, there are no doubts, even among experts in cancer chemotherapy and radiotherapy, that the immune system plays a vital role in tumor eradication. Following American approval, many clinical trials of cancer immunotherapy are being conducted. With this book the reader will readily understand the paradigm shift in cancer treatment and will realize the importance of cancer immunotherapy. The great value of immunotherapy will be obvious, not only for tumor shrinkage but for prolonging patient survival.